Information Provided By: 
Fly News Breaks for September 3, 2015
ACAD
Sep 3, 2015 | 09:40 EDT
After ACADIA submitted its New Drug Application for Nuplazid for treating Parkinson's psychosis to the FDA and requested priority review for the application, Ladenburg analyst Robert Hazlett said he believes the priority request will be granted, putting the drug on track for a likely U.S. introduction in 2016. The EU filing is not expected to be far and is also likely during 2016, said Hazlett, who believes that EU partnership talks are progressing. The analyst keeps a Buy rating and $43 price target on ACADIA shares.
News For ACAD From the Last 2 Days
There are no results for your query ACAD
